At a glance
ClinicalIndex Comparison RecordPhase 2Recruiting· 484 target
Drug / intervention
ZG005 Powder for Injection +1 morebiological
Likely dose
ZG005 Powder for Injection 0.3 mg/kgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
NCT06233292Phase 2RecruitingMonitorUpdated 24mo ago · Completion was 5mo agoSlow Enrollment
Long Recruiting
Monitor
A Phase 1/2 Dose Escalation, Tolerability, Safety and Pharmacokinetics Study of ZG005 in Patients With Advanced Solid Tumors
In Brief
A Phase 2 clinical trial evaluating ZG005 Powder for Injection for Solid Tumors. Currently recruiting, targeting 484 participants across 1 site.
Signals
Enrolling slower than its timeline implies
Detailed Summary
This is a multi-center, open-label, Phase 1/2 study of ZG005 for the treatment of subjects with advanced solid tumors, and consists of three stages: dose escalation and confirmation of MTD/recommended dose.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsSolid Tumors
CountriesChina
Collaborators--
Timeline
Phase 2RecruitingOverdue
2023202420252026
Enrollment StartJun 2022
First PostedJan 2024
Primary CompletionJan 2026
TodayJul 2026
First PostedJan 31, 2024
Enrollment StartJun 17, 2022
Primary CompletionJan 1, 2026
TodayJul 1, 2026
Enrollment to primary: 3.5 yearsPosted 2.4 years ago
Interventions
ZG005 Powder for Injectionbiological
The dose groups of ZG005 for dose escalations are set as 0.3 mg/kg, 1mg/kg, 3mg/kg, 10mg/kg, and 20mg/kg, intravenous infusion, once every 3 weeks.
ZG005 Powder for Injectionbiological
Recommended Phase 2 Dose (RP2D) of ZG005 monotherapy, intravenous infusion, once every 3 weeks.